[Federal Register Volume 66, Number 141 (Monday, July 23, 2001)]
[Notices]
[Page 38300]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-18280]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Therapeutic Blockage of 
ICER Synthesis To Prevent ICER-Mediated Inhibition of Immune Cell 
Activity

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive license to practice the inventions embodied in U.S. Patent 
Application No. 09/643,548 and International patent application 
entitled ``Therapeutic blockage of ICER synthesis to prevent ICER-
mediated inhibition of immune cell activity'', to Virimmune Inc., 
having a place of business in Rockville, Maryland. The patent rights of 
these inventions have been assigned to the United States of America.
    The prospective exclusive license territory will be worldwide and 
the field of use may be limited to the treatment of infectious disease 
and cancer.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
September 21, 2001 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comment and 
other materials relating to the contemplated exclusive license should 
be directed to: Percy S. Pan, Technology Licensing Specialist, Office 
of Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone 301-496-7736, 
ext. 256; Facsimile 301-402-0220; E-mail [email protected].

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be 
royalty-bearing and will comply with the terms and conditions of 35 
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be 
granted unless within sixty (60) days from the date of this published 
notice, the NIH receives written evidence and argument that establish 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: July 12, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 01-18280 Filed 7-20-01; 8:45 am]
BILLING CODE 4140-01-P